

**Matthew Krebs****Last DOI update: January 8, 2023****Financial Interests**

AstraZeneca, Expert Testimony, Institutional  
Bayer, Advisory Board, Personal  
Guardant Health, Advisory Board, Personal  
Janssen, Advisory Board, Personal  
Janssen, Invited Speaker, Personal  
Roche, Advisory Board, Personal  
Roche, Invited Speaker, Personal  
Seattle Genetics, Advisory Board, Institutional  
Astex, Local PI, Institutional, Financial interest  
AstraZeneca, Coordinating PI, Institutional, Financial interest  
Bayer, Local PI, Institutional, Financial interest  
BerGenBio, Local PI, Institutional, Financial interest  
Blueprint, Local PI, Institutional, Financial interest  
Carrick, Coordinating PI, Institutional, Financial interest  
Immutep, Local PI, Institutional, Financial interest  
Janssen, Coordinating PI, Institutional, Financial interest  
Novartis, Local PI, Institutional, Financial interest  
Novartis, Research Grant, Institutional, Financial interest  
Nurix, Local PI, Institutional, Financial interest  
Nuvalent, Local PI, Institutional, Financial interest  
Pyramid Biosciences, Coordinating PI, Institutional, Financial interest  
Roche, Local PI, Institutional, Financial interest  
Roche, Research Grant, Institutional, Financial interest  
Seattle Genetics, Local PI, Institutional, Financial interest  
Turning Point Therapeutics, Local PI, Institutional, Financial interest

**Other**

Immutep, Other, Travel expenses for congress  
Janssen, Other, Travel expenses for congress